{"url_path":"/sec/bbot/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-277513-index.html","accession_number":"0001193125-26-277513","cik":"0001869105","ticker":"BBOT","issuer_name":"BridgeBio Oncology Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-277513-index.html","primary_entity_key":"0001869105","primary_entity_name":"BridgeBio Oncology Therapeutics, Inc."},"word_count":314,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nThe proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 16, 2026, with each such proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”).\n\nThe number of shares of common stock entitled to vote at the Annual Meeting was 80,112,725. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 48,344,441. The number of votes cast for and against and the number of abstentions, broker non-votes and no votes with respect to each proposal voted upon are set forth below.\n\nProposal 1 - Election of Directors.\n\nThe Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.\n\n \n\nDirector Nominee\n  \nVotes For\n  \nVotes Withheld\n \n\nPeter Lebowitz, M.D., Ph.D.\n\n  \n31,822,504\n  \n \n3,372\n \n\nFrank P. McCormick, Ph.D., F.R.S., D. Sc.\n\n  \n25,654,119\n  \n \n6,171,757\n \n\nThere were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal.\n\nProposal 2 - Ratification of Appointment of Independent Registered Accounting Firm.\n\nThe Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.\n\n \n\nVotes For\n \nVotes Against\n \nAbstentions\n\n34,535,875\n \n3,440\n \n0\n\nThere were zero broker non-votes and 13,805,126 no votes regarding this proposal.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\n \nBRIDGEBIO ONCOLOGY THERAPEUTICS, INC.\n\nDate: June 22, 2026\n \n\n \nBy:\n \n\n/s/ Pedro J. Beltran, Ph.D.\n\n \n\n \n\n \n\nName: Pedro J. Beltran, Ph.D.\n\nTitle: Chief Executive Officer"}